Prescription Requirements and Patient Autonomy: Considering an Over-the-Counter Default
Madison Kilbride
Search for more papers by this authorSteven Joffe
Search for more papers by this authorHolly Fernandez Lynch
Search for more papers by this authorMadison Kilbride
Search for more papers by this authorSteven Joffe
Search for more papers by this authorHolly Fernandez Lynch
Search for more papers by this authorAbstract
When new drugs are approved by the Food and Drug Administration, the default assumption is that they will be available by prescription only, safe for use exclusively under clinical supervision. The paternalism underlying this default must be interrogated in order to ensure appropriate respect for patient autonomy. Upon closer inspection, prescription requirements are justified when nonprescription status would risk harm to third parties and when a large segment of the population would struggle to exercise their autonomy in using a drug safely and effectively on their own. Although these justifications can support prescription status for many drugs, we propose that reversing the FDA's current default to instead begin with a presumption in favor of over-the-counter status is the best way to avoid interference with valid claims of patient autonomy. Under this approach, a range of drug products could be considered for an OTC switch, including oral contraceptives, statins, and HIV-prevention drugs.
Notes
- 1M. K. Kilbride and S. Joffe, “The New Age of Patient Autonomy: Implications for the Patient-Physician Relationship,” Journal of the American Medical Association 320, no. 19 (2018): 1973–74; E. J. Topol, The Patient Will See You Now: The Future of Medicine Is in Your Hands (New York: Basic Books, 2015).
- 2 Roman, https://www.getroman.com/; Hers, https://www.forhers.com/; Hims, https://www.forhims.com/.
- 3Y. Gagne and B. Helm, “Buying Prescription Drugs Online Is Easier Than Ever. But There Are Side Effects,” Fast Company, September 11, 2019, https://www.fastcompany.com/90396205/buying-prescription-drugs-online-is-easier-than-ever-but-there-are-side-effects; H. Curtis and J. Milner, “Ethical Concerns with Online Direct-to-Consumer Pharmaceutical Companies,” Journal of Medical Ethics 46, no. 3 (2020): 168-71.
- 4D. S. Kazi, I. T. Katz, and A. K. Jha, “PrEParing to End the HIV Epidemic—California's Route as a Road Map for the United States,” New England Journal of Medicine 381 (2019): 2489–91; K. Zraick and S. E. Garcia, “California Makes H.I.V.-Prevention Drugs Available without a Prescription,” New York Times, October 9, 2019.
- 5T. Puzantian and J. J. Gasper, “Provision of Naloxone without a Prescription by California Pharmacists 2 Years after Legislation Implementation,” Journal of the American Medical Association 320 (2018): 1933–34; K. E. Evoy et al., “Naloxone Accessibility without a Prescriber Encounter under Standing Orders at Community Pharmacy Chains in Texas,” Journal of the American Medical Association 320 (2018): 1934-37.
- 6“ What's the Plan B Morning-After Pill?,” Planned Parenthood, 2019, https://www.plannedparenthood.org/learn/morning-after-pill-emergency-contraception/whats-plan-b-morning-after-pill.
- 7Kathleen Miller, senior economist, Office of Orphan Products Development, U.S. Food and Drug Administration, personal correspondence with Holly Fernandez Lynch, December 4, 2019 (on file with the authors).
- 8“ Innovative Approaches for Nonprescription Drug Products: Guidance for Industry (DRAFT GUIDANCE),” U.S. Food and Drug Administration, 2018, https://www.fda.gov/media/114328/download.
- 9J. Flanigan, “Respect Patients' Choices to Self-Medicate,” Cato Unbound, July 10, 2017, https://www.cato-unbound.org/2017/07/10/jessica-flanigan/respect-patients-choices-self-medicate; J. Flanigan, Pharmaceutical Freedom: Why Patients Have a Right to Self-Medicate (New York: Oxford University Press, 2017); J. Flanigan, “Three Arguments against Prescription Requirements,” Journal of Medical Ethics 38, no. 10 (2012): 579-86; A. Martin, “Commentary on ‘Three Arguments against Prescription Requirements,’” Journal of Medical Ethics 38, no. 10 (2012): 588-89; N. Eyal, “Reconciling Informed Consent with Prescription Drug Requirements,” Journal of Medical Ethics 38, no. 10 (2012): 589-91; J. S. Taylor, “The Value of Autonomy and the Right to Self-Medication,” Journal of Medical Ethics 38, no. 10 (2012): 587-88.
10.1093/oso/9780190684549.001.0001 Google Scholar
- 10R. S. Eisenberg, “The Role of the FDA in Innovation Policy,” Michigan Telecommunications and Technology Law Review 13, no. 2 (2007): 345–88; A. Kapczynski, “Dangerous Times: The FDA's Role in Information Production, Past and Future,” Minnesota Law Review 102 (2018): 2357-82.
- 11H. Fernandez Lynch and A. Bateman-House, “Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways,” Journal of Law, Medicine & Ethics 48, no. 2 (2020): 365–72.
- 12Eisenberg, “ The Role of the FDA.”
- 13P. B. Hutt, “A Legal Framework for Future Decisions on Transferring Drugs from Prescription to Nonprescription Status,” Food, Drug and Cosmetic Law Journal 37 (1982): 427–40.
- 14 Pure Food and Drug Act, Pub. L. 59-384 (1906).
- 15 Federal Food, Drug, and Cosmetic Act, Pub. L. 75-717 (1938).
- 16P. Temin, “The Origin of Compulsory Drug Prescriptions,” Journal of Law and Economics 22, no. 1 (1979): 91–106.
- 17Hutt, “ A Legal Framework”; Temin, “The Origin.”
- 18Temin, “ The Origin,” 97.
- 19 Durham-Humphrey Amendment, Federal Food, Drug, and Cosmetic Act, Pub. L. 82-515 (1951).
- 20 Kefauver-Harris Amendments, Federal Food, Drug, and Cosmetic Act, Pub. L. 87-781 (1962).
- 21 21 U.S.C. §?353 (b)(1) (2016).
- 22“ Drug Applications for Over-the-Counter (OTC) Drugs,” U.S. Food and Drug Administration, 2015, https://www.fda.gov/drugs/types-applications/drug-applications-over-counter-otc-drugs.
- 23“ How FDA Strives to Ensure the Safety of OTC Products,” U.S. Food and Drug Administration, 2016, https://www.fda.gov/drugs/special-features/how-fda-strives-ensure-safety-otc-products.
- 24 21 U.S.C. §353 (b)(3) (2016).
- 25“ Drugs: Adequate Directions for Use,” U.S. Food and Drug Administration, 21 C.F.R. §201.5 (1976).
- 26“ Standards for Safety, Effectiveness, and Labeling,” U.S. Food and Drug Administration, 21 C.F.R. §330.10(a)(4)(v) (2002).
- 27“ Frequently Asked Questions about CDER,” U.S. Food and Drug Administration, 2019, https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/frequently-asked-questions-about-cder#4.
- 28U.S. Food and Drug Administration, “ Guidance for Industry: Self-Selection Studies for Nonprescription Drug Products,” 2013, https://www.fda.gov/files/drugs/published/Self-Selection-Studies-for-Nonprescription-Drug-Products.pdf; U.S. Food and Drug Administration, “Guidance for Industry: Label Comprehension Studies for Nonprescription Drug Products,” 2010, https://www.fda.gov/media/75626/download.
- 29“ Division of Nonprescription Drugs,” U.S. Food and Drug Administration, 2018, https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/division-nonprescription-drugs.
- 30Hutt, “ A Legal Framework.”
- 31 Committee on Gynecologic Practice, “ACOG Committee Opinion Number 540: Risk of Venous Thromboembolism among Users of Drospirenone-Containing Oral Contraceptive Pills,” Obstetrics and Gynecology 120, no. 5 (2012): 1239–42.
- 32“ Acetaminophen Overdose,” MedLinePLus, National Institutes of Health, November 8, 2020, https://medlineplus.gov/ency/article/002598.htm.
- 33D. C. Throckmorton, “ FDA Update: 2018,” presented at the Consumer Healthcare Products Association Regulatory Scientific & Quality Conference, May 17, 2018 (for an outline and other slides, see https://www.fda.gov/media/113964/download); R. S. Mehta, “Nonprescription Drug Safe Use Regulatory Expansion (NSURE),” presented at the U.S. Food and Drug Administration's 2nd Annual Health Professional Organizations Conference, October 4, 2012 (for slides, see https://www.fda.gov/media/85156/download).
- 34U.S. Food and Drug Administration, “Notice of Public Hearing: Using Innovative Technologies and Other Conditions of Safe Use to Expand Which Drug Products Can Be Considered Nonprescription,” Federal Register 77, no. 39 (2012): 12059–62.
- 35“ Innovative Approaches for Nonprescription Drug Products,” U.S. Food and Drug Administration.
- 36B. van der Vossen, “Libertarianism,” Stanford Encyclopedia of Philosophy, 2019, https://plato.stanford.edu/entries/libertarianism/; S. Mill, On Liberty (London: J. W. Parker and Son, 1859).
- 37K. E. Fleming-Dutra et al., “Prevalence of Inappropriate Antibiotic Prescriptions among U.S. Ambulatory Care Visits, 2010-2011,” Journal of the American Medical Association 315, no. 17 (2016): 1864–73; E. P. Brass, “Changing the Status of Drugs from Prescription to Over-the-Counter Availability,” New England Journal of Medicine 345, no. 11 (2001): 810-16; A. Bateman-House, “Don't Let Medical Autonomy Become Abandonment,” Cato Unbound, July 13, 2017, https://www.cato-unbound.org/2017/07/13/alison-bateman-house/dont-let-medical-autonomy-become-abandonment; C. Klugman, “Often, Doctor Knows Best,” Cato Unbound, July 17, 2017, https://www.cato-unbound.org/2017/07/17/craig-klugman/often-doctor-knows-best.
- 38“ About FDA Product Approval,” U.S. Food and Drug Administration, 2017, https://www.fda.gov/news-events/approvals-fda-regulated-products/about-fda-product-approval.
- 39Flanigan, Pharmaceutical Freedom.
- 40J. Savulescu, “Rational Non-interventional Paternalism: Why Doctors Ought to Make Judgments of What Is Best for Their Patients,” Journal of Medical Ethics 21, no. 6 (1995): 327–31.
- 41J. Feinberg, Harm to Self (Oxford: Oxford University Press, 1986).
- 42G. W. Rainbolt, “Prescription Drug Laws: Justified Hard Paternalism,” Bioethics 3, no. 1 (1989): 45–58.
- 43S. Conly, Against Autonomy: Justifying Coercive Paternalism (Cambridge: Cambridge University Press, 2012).
10.1017/CBO9781139176101 Google Scholar
- 44 Bateman-House, “Don't Let Medical Autonomy”; C. Sandefur, “Tear Up the Permission Slip: Medical Autonomy Is a Fundamental Right,” Cato Unbound, July 19, 2017, https://www.cato-unbound.org/2017/07/19/christina-sandefur/tear-permission-slip-medical-autonomy-fundamental-human-right.
- 45Savulescu, “Rational Non-interventional Paternalism”; C. R. Sunstein and R. H. Thaler, “Libertarian Paternalism Is Not an Oxymoron,” University of Chicago Law Review 70 (2003): 1159–1202.
- 46Flanigan, “ Three Arguments.”
- 47Brass, “ Changing the Status.”
- 48F. G. Miller and A. Wertheimer, “Facing Up to Paternalism in Research Ethics,” Hastings Center Report 37, no. 3 (2007): 24–34.
- 49U.S. Food and Drug Administration, “ Guidance for Industry: Self-Selection Studies”; U.S. Food and Drug Administration, “Guidance for Industry: Label Comprehension Studies.”
- 50U.S. Food and Drug Administration, “ Innovative Approaches for Nonprescription Drug Products.”
- 51U.S. Food and Drug Administration, “ Notice of Public Hearing: Using Innovative Technologies.”
- 52 Ibid.
- 53“Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine, Ephedrine, and Phenylpropanolamine,” U.S. Food and Drug Administration, 2017, https://www.fda.gov/drugs/information-drug-class/legal-requirements-sale-and-purchase-drug-products-containing-pseudoephedrine-ephedrine-and; T. A. Wilkinson et al., “Access to Emergency Contraception After Removal of Age Restrictions,” Pediatrics 140, no. 1 (2017): e20164262.
- 54U.S. Food and Drug Administration, “ Notice of Public Hearing: Using Innovative Technologies.”
- 55G. Dworkin, “Paternalism,” Monist 56, no. 1 (1972): 64–84.
- 56K. Eder, “7 OTC Product Categories Completely Covered by Insurance,” Pharmacy Times, December 8, 2015, https://www.pharmacytimes.com/news/8-otc-product-categories-completely-covered-by-insurance.
- 57M. Petersen, “A Push to Sell Top Allergy Drugs over the Counter,” New York Times, May 11, 2001.
- 58Fleming-Dutra et al., “Prevalence of Inappropriate Antibiotic Prescriptions”; Kaiser Family Foundation, “Medicaid Benefits: Over-the-Counter Products,” 2018, https://www.kff.org/other/state-indicator/medicaid-benefits-over-the-counter-products/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D; E. Tahmincioglu, “Over the Counter, Yes, but Out of the Insurance Plan,” New York Times, July 4, 2004.
- 59“ Innovative Approaches for Nonprescription Drug Products,” U.S. Food and Drug Administration.
- 60L. Larner, “New Health Policy Brief: Off-Label Drug Promotion,” Health Affairs Blog, July 6, 2016, https://www.healthaffairs.org/do/10.1377/hblog20160706.055728/full/.
- 61“ FDA Adverse Events Reporting System (FAERS) Public Dashboard,” U.S. Food and Drug Administration, 2019, https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis.
- 62S. Stergiopoulos et al., “A Survey of Adverse Event Reporting Practices among U.S. Healthcare Professionals,” Drug Safety 39, no. 11 (2016): 1117–27.
- 63D. Kamerow, “Science Trumps Politics on Emergency Contraception,” British Medical Journal 346 (2013): f2217; D. A. Grimes, “Emergency Contraception: Politics Trumps Science at the U.S. Food and Drug Administration,” Obstetrics and Gynecology 104, no. 2 (2004): 220-21; J. M. Drazen, M. F. Greene, and A. J. Wood, “The FDA, Politics, and Plan B,” New England Journal of Medicine 350, no. 15 (2004): 1561-62; K. K. Sindhu and E. Y. Adashi, “Over-the-Counter Oral Contraceptives to Reduce Unintended Pregnancies,” Journal of the American Medical Association 324 (2020): 939-40.
- 64“ Free to Choose Medicine,” The Heartland Institute, November 8, 2020, https://www.heartland.org/Center-Health-Care/free-to-choose-medicine/index.html; “Right to Try,” U.S. Food and Drug Administration, 2019, https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try; Conditional Approval Act, H.R. 5497 (introduced 2019), https://www.congress.gov/bill/116th-congress/house-bill/5497.
- 65Eyal, “ Reconciling Informed Consent.”
- 66D. Grossman and L. Fuentes, “Over-the-Counter Access to Oral Contraceptives as a Reproductive Healthcare Strategy,” Current Opinion in Obstetrics and Gynecology 25, no. 6 (2013): 500–505; D. Grossman et al., “Accuracy of Self-Screening for Contraindications to Combined Oral Contraceptive Use,” Obstetrics and Gynecology 112, no. 3 (2008): 572-78; Shotorbani et al., “Agreement between Women's and Providers' Assessment of Hormonal Contraceptive Risk Factors,” Contraception 73, no. 5 (2006): 501-6.